NSAID developer Iroko Pharmaceuticals postpones IPO

By
A A A

Iroko Pharmaceuticals, which is developing high-efficacy, low-dose NSAID therapeutics, postponed its IPO on Tuesday citing poor market conditions. The Philadelphia, PA-based company was founded in 2007 and booked $10 million in sales for the 12 months ended March 31, 2013. Iroko Pharmaceuticals initially filed confidentially on March 1, 2013. Jefferies, William Blair and Canaccord Genuity were set to be the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: IRKO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

3,093,564
  • $98.796 ▲ 1.15%
2,638,389
  • $16.199 ▼ 0.07%
2,545,160
  • $2.11 ▼ 34.27%
2,475,372
  • $168.7102 ▼ 7.33%
2,446,945
  • $14.255 ▼ 4.52%
2,330,983
  • $36.425 ▼ 3.82%
2,302,030
  • $14.12 ▲ 2.69%
2,074,828
  • $43.05 ▼ 1.33%
As of 10/20/2014, 09:36 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com